Recently, intravenous supplementation with a complex of recombinant human (rh)IGF-1 and IGF binding protein-3 (rhIGF-1/rhIGFBP-3) to hospitalized preterm infants indicated benefits to decrease the incidence of bronchopulmonary dysplasia (BPD) and intraventricular hemorrhage (IVH) (Ley et al., 2019; Horsch et al., 2020). This evidence concerns the gene IGF1 and bronchopulmonary dysplasia.